Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDSBusiness Wire • 12/13/24
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior TherapiesBusiness Wire • 12/10/24
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with MyelofibrosisBusiness Wire • 12/10/24
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and DevelopmentBusiness Wire • 11/11/24
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon AdvisorsBusiness Wire • 11/07/24
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire • 11/07/24
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic MalignanciesBusiness Wire • 11/05/24
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial OfficerBusiness Wire • 09/09/24
Geron Corporation Reports Second Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 08/08/24
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDSBusiness Wire • 07/26/24
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024Business Wire • 07/23/24